COPD

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A new study shows consistent confidence and anxiety of self-care with the injectable biologic in patients with asthma.

An assessment of a combined pharmacologic and cognitive behavioral therapy program shows patients improve FEV1, FVC, and other metrics.

Despite being advised in clinical guidelines, fewer than 2% of COPD patients initiate pulmonary rehabilitation within 90 days of hospitalization.

California is home of the cities with the most unhealthy pollution levels, according to the newest annual report from the ALA.

ALA chief medical officer Al Rizzo, MD, discusses plans to kickstart vaccine research and public health preventive measures.

COPD patients with unnoticed OSA are at a greater risk of hospital readmission and even all-cause mortality.

Al Rizzo, MD, of the American Lung Association, discusses some of the biggest challenges and questions raised on lung health during the coronavirus pandemic.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

A study of 416 hospitalized patients indicates 19.7% suffered cardiac injury, which was also associated with increased ventilation and mortality.

New expanded analysis from the IMPACT trial shows FF/UMEC/VI's benefit versus dual inhaler therapies.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

The new low nicotine products contain 95% less nicotine than the top 100 cigarette brands in the US, according to 22nd Century Group.

A new guidance breaks ground as the first of its kind to assist physicians in screening for, and treating, vaping-associated respiratory disease syndrome.

New follow-up data shows older patients with COPD characterized by high blood eosinophil counts may benefit from the biologic.

New VDAART follow-up findings show at-risk children are not safer from asthma or recurrent wheeze when their mother takes prenatal vitamin D.

New research into the role of legislation on vaping use shows certain laws may be more effective than others.

New cohort data shows significantly worsened respiratory symptoms among patients with comorbid cough and COPD.

The FDA will rule on the type 2 inflammation-targeting biologic for another indication this May.

New data shows the market-controlling e-cigarette product nearly doubled its rate of young adult users in just 1 year.